loading
loading
Search fieldHome page Seeking Alpha - Power to InvestorsSearch for Symbols, analysts, keywordsAbout PremiumCreate free accountLog in Earnings Call Insights Neogen outlines FY 2027 revenue of $885M-$890M and adjusted EBITDA of $181M-$183M as Petrifilm transfer nears start Oct 06, 2026, 7:13 PM ETNeogen Corporation (NEOG) StockAI-Generated Earnings Calls Insights Earnings Call Insights: Neogen (NEOG) Q1 FY 2027 Management View CEO Mikhael Nassif framed FY 2027 as the shift from “stabilization and foundation building” to “scaling those fundamentals to drive more consistent execution, better outcomes for customers and profitable growth,” and said Q1 showed “solid core Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our feedback forum. If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. Search fieldEntering text into the input field will update the search result below Quick Insights Solid core revenue growth in Food and Animal Safety segments, order timing benefits, early commercial wins, and operational milestones like Petrifilm validation prompted management to increase full-year forecasts. Management expects margins to stay flat in the first half due to intensified investment in innovation and commercial infrastructure, with future improvement expected as operational programs become more impactful in the latter part of the year. Core risks include order timing distorting quarter comparisons, execution risk in Petrifilm manufacturing transfer, inventory and supply-chain challenges, and the pending genomics divestiture subject to regulatory approvals. Recommended For You
document fetched 2026-10-07 02:56 · canonical https://seekingalpha.com/news/4650780-neogen-outlines-fy-2027-revenue-of-885m-890m-and-adjusted-ebitda-of-181m-183m-as-petrifilm?feed_item_type=news